Mechanisms involved in suppression of ADAMTS4 expression in synoviocytes by high molecular weight hyaluronic acid

Biochemical and Biophysical Research Communications

Volumn 432, Issue 4, 2013, Pages 580-585

  Kataoka, Yoshihiro ^a   Ariyoshi, Wataru ^a   Okinaga, Toshinori ^a   Kaneuji, Takeshi ^a   Mitsugi, Sho ^a   Takahashi, Tetsu ^b   Nishihara, Tatsuji ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

ADAMTS4; CD44; Hyaluronan; JNK; P38 MAPK; Synoviocyte

Indexed keywords

AGGRECANASE 1; HIGH MOLECULAR WEIGHT HYALURONIC ACID; HYALURONIC ACID; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIOCYTE; WESTERN BLOTTING;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CELL LINE; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; HYALURONIC ACID; INTERLEUKIN-1BETA; MAP KINASE KINASE 4; MOLECULAR WEIGHT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROCOLLAGEN N-ENDOPEPTIDASE; RNA, MESSENGER; SYNOVIAL FLUID; SYNOVITIS;

EID: 84875512003     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.043     Document Type: Article

References (34)

1. Clements K.M., Price J.S., Chambers M.G., et al. Gene deletion of either interleukin-1β, interleukin-1β-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 after surgical transection of the medial collateral ligament and patrial medial meniscectomy. Arthritis Rheum. 2003, 48:3452-3463.
2. Goldring M.B., Goldring S.R. Osteoarthritis. J. Cell Physiol. 2007, 213:626-634.
3. Arner E.C., Pratta M.A., Decicco C.P., et al. Aggrecanase. A target for the design of inhibitors of cartilage degradation. Ann. N. Y. Acad. Sci. 1999, 878:92-107.
4. Porter S., Clark I.M., Kevorkian L., et al. The ADAMTS metalloproteinases. Biochem. J. 2005, 386:15-27.
5. Rodriguez-Manzaneque J.C., Westling J., Thai S.N., et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. 2002, 293:501-508.
6. Collins-Racie L.A., Flannery C.R., Zeng W., et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol. 2004, 23:219-230.
7. Somerville R.P., Longpre J.M., Jungers K.A., et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J. Biol. Chem. 2003, 278:9503-9513.
8. Brown T.J., Laurent U.B., Fraser J.R. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp. Physiol. 1991, 76:125-134.
9. Goldring M.B. Osteoarthritis and cartilage: the role of cytokines. Curr. Rheumatol. Rep. 2000, 2:459-465.
10. Takao M., Okinaga T., Ariyoshi W., et al. Role of heme oxygenase-1 in inflammatory response induced by mechanical stretch in synovial cells. Inflamm. Res. 2011, 60:861-867.
11. Lefebvre V., Peeters-Joris C., Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim. Biophys. Acta 1990, 1052:366-378.
12. Csaki C., Mobasheri A., Shakibaei M. Synergistic chondroprotectiive effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apotosis. Arthritis Res. Ther. 2009, 11:R165.
13. Hashizume M., Mihara M. High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1. Biochem. Biophys. Res. Commun. 2010, 403:184-189.
14. Liu Y.Z., Jackson A.P., Cosgrove S.D. Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage 2009, 17:1333-1340.
15. Nanki T., Nagasaka K., Hayashida K., et al. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Immunol. 2001, 167:5381-5385.
16. Hussein M.R., Fathi N.A., El-Din A.M., et al. Alterations of the CD4(+), CD8(+) T cell subsets, interleukins-1beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol. Oncol. Res. 2008, 14:321-328.
17. Lark M.W., Bayne E.K., Flanagan J., et al. Aggrecan degradation in human cartilage: evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J. Clin. Invest. 1997, 100:93-106.
18. Moulharat N., Lesur C., Thomas M., et al. Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis Cartilage 2004, 12:296-305.
19. Stanton H., Rogerson F.M., East C.J., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
20. Smith M.M., Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol. Int. 1987, 7:113-122.
21. Lazaro J.S., Herraez S.S., Gallego L.D., et al. Spontaneous patella dislocation in Rubinstein-Taybi syndrome. Knee 2007, 14:68-70.
22. Teder P., Vandivier R.W., Jiang D., et al. Resolution of lung inflammation by CD44. Science 2002, 296:155-158.
23. Wang C.T., Lin Y.T., Chiang B.L., et al. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 12:1237-1247.
24. Takahashi T., Tominga K., Takano H., et al. A decrease in the molecular weight of hyaluronic acid in synovial fluid from patients with temporomandibular disorders. J. Oral Pathol. Med. 2004, 33:224-229.
25. Balazs E.A. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg. Technol. Int. 2004, 12:278-289.
26. Kolarz G., Kotz R., Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalugan) in patients with osteoarthritis of the knee. Semin. Arthritis Rheum. 2003, 32:310-319.
27. Goldberg V.M., Buckwalter J.A. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage 2005, 13:216-224.
28. Underhill C. CD44: the hyaluronan receptor. J. Cell Sci. 1992, 103:293-298.
29. Rosengren S., Boyle D.L., Firestein G.S. Acquisition culture and phenotyping of synovial fibroblasts. Methods Mol. Med. 2007, 135:365-375.
30. Julovi S.M., Ito H., Nishitani K., et al. Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J. Orthop. Res. 2011, 29:258-264.
31. Kapoor M., Martel-Pelletier J., Lajeunesse D., et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7:33-42.
32. Polzer K., Joosten L., Gasser J., et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 2010, 69:284-290.
33. Han Z., Boyle D.L., Bennett B., et al. Activation of Jun amino terminal kinase in rheumatoid arthritis synoviocytes. Arthritis Rheum. 1991, 291:124-130.
34. Yatabe T., Mochizuki S., Takizawa M., et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann. Rheum. Dis. 2009, 68:1051-1058.